Sep 7, 2026 · 25 min · 11 segments
Send us Fan Mail **About Dr. Browning** Christopher J. Browning, OD, is a Greenwood native who is proud to follow his dream of providing eye care…
Christopher J. BrowningGuest
David KadingHost
What do you think is the thing that has helped you grow over the years more than anything else in the myopia management space?
I think it's a word of mouth from parents and then our colleagues, you know, all our friends around us who for years, you know, didn't feel comfortable with myopia management, or maybe they felt comfortable, you know, helping the 12-year-old who was a minus two, but they didn't feel comfortable with a kid who was seven years old and already a minus six.
So I think just people recognizing that we had a true passion for it and that we have a lot of experience for it, referrals from our colleagues.
And what do you think, what are you seeing as the future, how things are changing in the next coming couple of years? I ask a lot of people this question and it's kind of interesting because admittedly, we've had a swarm of products, of companies, of concepts, you that have come in and it seems like it's all rushing in at us pretty quickly.
You know, I think with the advent of the new spectacle lenses you know, We have already, in our practice, seen a tremendous growth in the dual therapy.
Kids who've been on atropine for a while, they weren't good candidates for contact lenses for whatever reason.
I think some of the studies that are going to come out are going to show that that's incredibly helpful.
I I'm really excited to see some of the new products even some of the new soft lenses that are coming out and what they have to offer some of the new specimen lenses designs that are going to come out uh are pretty it are I'm very interested to see what the studies have shown with them I know that we've been promised for a while that we'll have some FDA approved uh you know atropine drops it'll be interesting to see what those concentrations are like what the studies have shown and how those are accepted um but In my mind, using different combinations of therapies, at least for the intermediate future, is going to be one of the most interesting things to see.
Dual therapy is something that seems to hopefully continue to be a bigger deal.
Possibly an approved atropine, which hopefully we have within the next 12 months.
But one of the things I am worried about, and I'd like to hear your take on this, is we talk about myopia management.
And Michael Lipson was on the podcast and he had written a letter to the editor defining those two terms in that myopia control is when you prescribe something and you see somebody back a year later.
What do you think is the thing that has helped you grow over the years more than anything else in the myopia management space?
I think it's a word of mouth from parents and then our colleagues, you know, all our friends around us who for years, you know, didn't feel comfortable with myopia management, or maybe they felt comfortable, you know, helping the 12-year-old who was a minus two, but they didn't feel comfortable with a kid who was seven years old and already a minus six.
So I think just people recognizing that we had a true passion for it and that we have a lot of experience for it, referrals from our colleagues.
And what do you think, what are you seeing as the future, how things are changing in the next coming couple of years? I ask a lot of people this question and it's kind of interesting because admittedly, we've had a swarm of products, of companies, of concepts, you that have come in and it seems like it's all rushing in at us pretty quickly.
You know, I think with the advent of the new spectacle lenses you know, We have already, in our practice, seen a tremendous growth in the dual therapy.
Kids who've been on atropine for a while, they weren't good candidates for contact lenses for whatever reason.
I think some of the studies that are going to come out are going to show that that's incredibly helpful.
I I'm really excited to see some of the new products even some of the new soft lenses that are coming out and what they have to offer some of the new specimen lenses designs that are going to come out uh are pretty it are I'm very interested to see what the studies have shown with them I know that we've been promised for a while that we'll have some FDA approved uh you know atropine drops it'll be interesting to see what those concentrations are like what the studies have shown and how those are accepted um but In my mind, using different combinations of therapies, at least for the intermediate future, is going to be one of the most interesting things to see.
Dual therapy is something that seems to hopefully continue to be a bigger deal.
Possibly an approved atropine, which hopefully we have within the next 12 months.
But one of the things I am worried about, and I'd like to hear your take on this, is we talk about myopia management.
And Michael Lipson was on the podcast and he had written a letter to the editor defining those two terms in that myopia control is when you prescribe something and you see somebody back a year later.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
